Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lixte Biotechnology Holdings, a developer of improved treatments for cancer and improved methods for detecting cancer, has appointed Mel Sorensen to its board of directors.
Subscribe to our email newsletter
Dr Sorensen is currently board director, president and CEO of Ascenta Therapeutics. Dr Sorensen is an experienced leader and administrator in cancer therapeutics and cancer drug development.
John Kovach, CEO of Lixte Biotechnology Holdings, said: “Mel is internationally recognized for his expertise in clinical oncology and in meeting the challenges of cancer drug development.
“In addition to his depth of knowledge and experience in applied cancer research, he has demonstrated remarkable administrative skills in bringing together the expertise of the diverse groups needed for the effective and safe development of important new anticancer drugs.”